Abstract
AbstractThe Australian nuclear medicine landscape is a vibrant mix of public and private sector facilities providing not only high-quality routine care to patients, but also cutting-edge research in diagnostic and therapeutic nuclear medicine. Australia’s unique regulatory framework, its relatively well-funded health system and its long-established rigorous training of physicians and supporting staff, has stimulated more rapid growth and earlier adoption of theranostics and therapeutic nuclear oncology when compared to many other countries around the world. More recently, interest and successful deployment of clinical trials networks across the country is helping obtain the data required to propel these new agents into clinical practice. The evolution of therapeutic nuclear oncology from the early days of I-131 use to the development of the Australasian Radiopharmaceutical Trials Network (ARTNET) and some of the factors for the Australian competitive advantage in this space will be discussed in this chapter.
Publisher
Springer International Publishing